SCHEMBL4030663

SCHEMBL4030663

Cc1c(Cl)ccc(S(=O)(=O)NCCC(N)=O)c1Cl

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
WDR5 P61964 1/20 0.46
FABP4 P15090 1/20 0.42
POLB P06746 2/20 0.41
ALDH1A1 P00352 8/20 0.40
MAPT P10636 4/20 0.40
LMNA P02545 3/20 0.40
CYP1A2 P05177 1/20 0.39
CYP3A4 P08684 1/20 0.39
CYP2C19 P33261 1/20 0.39
MEN1 O00255 2/20 0.39
KMT2A Q03164 2/20 0.39
GSTO1 P78417 2/20 0.38
CSNK1A1 P48729 1/20 0.38
CSNK1D P48730 1/20 0.38
CSNK1E P49674 1/20 0.38
CSNK1G2 P78368 1/20 0.38
CSNK1G1 Q9HCP0 1/20 0.38
F10 P00742 1/20 0.37
PRSS1 P07477 1/20 0.37
PRSS2 P07478 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4029646 0.86 WDR5 (0.48) WDR5FABP4POLBALDH1A1CYP1A2
SCHEMBL6761723 0.76 WDR5 (0.47) WDR5POLBALDH1A1GSTO1
SCHEMBL4029240 0.75 ALDH1A1 (0.54) POLBALDH1A1CYP1A2CYP3A4CYP2C19
SCHEMBL6766636 0.74 ALDH1A1 (0.45) WDR5POLBALDH1A1LMNACYP1A2
SCHEMBL5119706 0.73 WDR5 (0.47) WDR5FABP4POLBALDH1A1LMNA
SCHEMBL5119703 0.73 WDR5 (0.47) WDR5FABP4POLBALDH1A1LMNA
SCHEMBL6763294 0.72 SMN1; SMN2 (0.44) WDR5POLBALDH1A1MAPTLMNA
SCHEMBL4030951 0.72 WDR5 (0.50) WDR5POLBALDH1A1LMNAKMT2A
SCHEMBL6761682 0.69 PKM (0.61) POLBCYP1A2CYP3A4CYP2C19CSNK1A1
SCHEMBL4033630 0.69 WDR5 (0.48) WDR5POLBALDH1A1MAPTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1521744-B1 ARYLSULPHONAMIDE DERIVATIVES AND USE THEREOF AS B1 BRADYKININ RECEPTOR ANTAGONISTS FOURNIER LAB SA (FR) 2009-04-01 EP disclosed
US-7361687-B2 Arylsulphonamide derivatives and methods of preparing LABORATOIRES FOURNIER SA (FR) 2008-04-22 US disclosed
US-20060084699-A1 Novel arylsulphonamide derivatives and use thereof as therapeutic agents LABORATOIRES FOURNIER SA (FR) 2006-04-20 US disclosed
EP-1521744-A1 ARYLSULPHONAMIDE DERIVATIVES AND USE THEREOF AS B1 BRADYKININ RECEPTOR ANTAGONISTS LABORATOIRES FOURNIER S.A. (FR) 2005-04-13 EP disclosed
WO-2003106428-A1 NOVEL ARYLSULPHONAMIDE DERIVATIVES AND USE THEREOF AS THERAPEUTIC AGENTS LABORATOIRES FOURNIER SA (FR) 2003-12-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060084699-A1 Novel arylsulphonamide derivatives and use thereof as therapeutic agents UGT1A1, UGT2B7, UGT1A6 WDR5 3992/4885FABP4 2346/4885POLB 1783/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.